Cannabis Report
Home > Boards > US OTC > Biotechs >

Oxford BioMedica PLC (OXBDF)

OXBDF RSS Feed
Add OXBDF Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 6/18/2018 1:21:20 PM - Followers: 7 - Board type: Free - Posts Today: 0

Oxford BioMedica PLC (OXBDF) 
 
Trades In UK as (OXB.L)
  
  
Company website

UK company traded on grey's in US

 

 
Company Address:
Medawar Centre
Robert Robinson Avenue
Oxford, OX4 4GA
United Kingdom - Map
Phone: 44 18 6578 3000
Fax: 44 18 6578 3001

 
Oxford BioMedica plc, a biopharmaceutical company, develops gene-based medicines and therapeutic vaccines for the treatment of cancer, and age-related or inherited neurodegenerative disorders and ocular diseases. Its LentiVector gene delivery technology platform targets non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes. The company is developing ProSavin, which has completed Phase I/II trials for the treatment of Parkinson's disease; RetinoStat that is in Phase I trial for ?wet? age-related macular degeneration; StarGen, which is in Phase I/IIa trial for the treatment of Stargardt disease; UshStat that is in Phase I/IIa trial for Usher syndrome type 1B; EncorStat, which is Phase I/II trial preparation for the prevention of corneal graft rejection; and Glaucoma-GT, which is in pre-clinical stage for the treatment of chronic glaucoma. It is also developing TroVax that is in Phase II trial for colorectal cancer and mesothelioma; and Anti-5T4 antibody, which is in pre-clinical stage for the treatment of cancer. In addition, the company is developing MoNuDin for the treatment of motor neuron disease. It has collaborations and licensing agreements with Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, and ImaginAb. Oxford BioMedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
 
Management
 
Partnerships 
 
Financial Reports:  http://www.oxfordbiomedica.co.uk/financial-reports/
 
Investor Contacts:  http://www.oxfordbiomedica.co.uk/investor-contacts/
 
 
 
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

 
 
 
 
 
 
Cannabis Report
OXBDF
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#649   OXB is trading for 1000 pence on the georgejjl 06/18/18 01:21:20 PM
#648   http://www.hardmanandco.com/docs/default-source/company-docs/oxford-biomedica-do marcusl2 06/14/18 09:20:08 AM
#647   HTTPS://edge.media-server.com/m6/p/bmeuzv3m HTTP://investors.axovant.com/inve marcusl2 06/14/18 09:19:01 AM
#646   http://www.ocquila.com/ Oxford Biomedica, "The unambiguous world leaders in marcusl2 06/14/18 09:17:52 AM
#645   For Oxford Biomedica, the deal is evidence of marcusl2 06/14/18 09:16:32 AM
#644   Thanks George, I`ll share that. It`s looking very marcusl2 06/14/18 01:28:57 AM
#643   Sheila Roy is a true pioneer georgejjl 06/13/18 11:14:45 AM
#642   "....AXO-Lenti-PD gene therapy has been developed by reengineering georgejjl 06/13/18 11:05:06 AM
#641   Since OXB (OXB.L) is trading at about 979.67 georgejjl 06/13/18 10:06:59 AM
#640   Oops! Slight climb today of 58% (at 11am)!! ADVFN_doclee 06/11/18 06:05:29 AM
#639   FT Buy OXB marcusl2 06/10/18 06:39:58 AM
#638   Oxford biotech seals $842 million deal for experimental georgejjl 06/07/18 07:49:54 AM
#637   Sheila Roy after a single treatment of ProSavin georgejjl 06/06/18 07:36:43 PM
#636   Sheila Roy after a single treatment of ProSavin georgejjl 06/06/18 07:36:39 PM
#635   Under the terms of the agreement, Oxford BioMedica georgejjl 06/06/18 07:30:19 PM
#634   $842.5 Million + $100 Million + $100 Million=???? georgejjl 06/06/18 07:26:06 PM
#633   Oxford BioMedica and Axovant Sciences enter into a georgejjl 06/06/18 07:17:39 PM
#632   Sheila Roy a pioneering patient for Prosavin georgejjl 06/06/18 07:01:24 PM
#631   https://seekingalpha.com/news/3361933-axovant-licenses-oxbminus-102-parkinson-s- marcusl2 06/06/18 07:23:23 AM
#630   The University of Pennsylvania has licensed technologies involved marcusl2 05/30/18 04:11:39 PM
#629   Penn Medicine’s Carl June, MD, Named One of georgejjl 05/29/18 11:08:11 PM
#628   PramBigear 29 May '18 - 21:17 - 196 of 205 marcusl2 05/29/18 05:55:52 PM
#627   Expansion plans and fundraise georgejjl 05/28/18 01:12:27 AM
#626   I think this is the start of the marcusl2 05/26/18 05:04:39 PM
#625   After a 1 share for 50 shares reverse georgejjl 05/16/18 08:58:37 PM
#624   A novel 5T4-targeting antibody-drug conjugate H6-DM4 exhibits potent georgejjl 05/16/18 07:23:01 PM
#623   In the coming months, we also intend to marcusl2 05/15/18 04:58:10 PM
#622   In the long term we anticipate that OXB’s marcusl2 05/10/18 10:06:07 AM
#621   Findings from the study suggest that CTL019, despite marcusl2 05/09/18 04:59:17 AM
#620   OXB are doing a share consolidation of 50-1. marcusl2 05/05/18 04:31:27 AM
#619   624 - The Use of Automation in the marcusl2 05/03/18 03:32:32 AM
#618   $GILD Yescarta Q1 sales $40M beat consensus of marcusl2 05/01/18 05:12:54 PM
#617   DLBCL approved https://novartis.gcs-web.com/Kymriah-tisagenlecleucel-first-in-c marcusl2 05/01/18 04:52:33 PM
#616   In April we announced an agreement to acquire marcusl2 04/20/18 04:51:02 AM
#615   https://seekingalpha.com/article/4164128-novartis-ag-2018-q1-results-earnings-ca marcusl2 04/19/18 04:35:08 PM
#614   More work and royalties for OXB marcusl2 04/19/18 04:31:03 PM
#613   Kudos! On the grey sheet with a JUST 10-11-12 04/16/18 10:53:40 PM
#612   Could it be that Novartis is negotiating to georgejjl 04/16/18 09:42:28 PM
#611   OXBDF up 117.88% today Monday April 16, 2018 georgejjl 04/16/18 08:11:20 PM
#610   Vulpes buy marcusl2 04/11/18 03:44:10 PM
#609   Pancreatic cancer therapy with combined mesothelin-redirected chimeric antige georgejjl 04/10/18 08:33:18 PM
#608   Novartis bets big on gene therapy with $8.7 georgejjl 04/09/18 07:59:56 PM
#607   Advances in Cancer Immunotherapy for Lymphoma georgejjl 04/06/18 01:46:21 PM
#606   Great stuff thanks George. A deal for it marcusl2 04/04/18 05:11:27 AM
#605   Click and read the pdf file georgejjl 04/03/18 07:50:54 PM
#604   Preclinical Assessment of CAR T-Cell Therapy Targeting the georgejjl 04/03/18 07:39:15 PM
#603   The 5T4 oncofetal glycoprotein does not act as georgejjl 04/03/18 07:35:12 PM
#602   The breast cancer antigen 5T4 interacts with Rab11, georgejjl 04/03/18 07:32:27 PM
#601   more than 2 companies very interested in Prosavin marcusl2 03/20/18 04:13:27 PM
#600   http://www.hardmanandco.com/docs/default-source/company-docs/oxford-biomedica-do marcusl2 03/20/18 05:04:28 AM
PostSubject